成人急性双相抑郁药物干预疗效与耐受性比较:系统综述与网络Meta分析
奥氮平联合氟西汀、喹硫平、奥氮平、鲁拉西酮、鲁美哌隆、卡利拉嗪和拉莫三嗪在减轻抑郁症状方面优于安慰剂,证据置信度为中等。抗抑郁药类别可能有效但躁狂转换风险高于抗精神病药,各药物副作用谱不同。
要点
- 奥氮平联合氟西汀、喹硫平、奥氮平、鲁拉西酮、鲁美哌隆、卡利拉嗪和拉莫三嗪优于安慰剂。
- 抗抑郁药类别可能有效,但躁狂转换风险高于抗精神病药。
- 各药物副作用谱存在差异,证据置信度中等。
核心结论
- 奥氮平联合氟西汀、喹硫平、奥氮平、鲁拉西酮、鲁美哌隆、卡利拉嗪和拉莫三嗪在成人急性双相抑郁中优于安慰剂。
- 抗抑郁药类别可能有效但躁狂转换风险高于抗精神病药,各药物副作用谱不同。
研究设计与样本
- 系统综述与网络Meta分析,检索MEDLINE、Embase、PsycINFO等数据库从建库至2023年4月13日。
- 纳入标准为疗程2-16周、盲法结局评估,包括联合、添加和单药治疗研究。
主要发现
- 奥氮平联合氟西汀、喹硫平、奥氮平、鲁拉西酮、鲁美哌隆、卡利拉嗪和拉莫三嗪在减轻抑郁症状方面优于安慰剂,SMD范围从奥氮平联合氟西汀的0·41(95%CI 0·19-0·64)到拉莫三嗪的0·16(95%CI 0·03-0·29)。
- 其他多种药物可能有效,但证据置信度极低至低。
- 抗抑郁药类别可能有效,但躁狂转换风险高于抗精神病药。
- 各药物副作用谱存在差异。
关键数值与推荐
- 共主要结局为抑郁症状(标准化均数差SMD)和躁狂转换(比值比OR)。
- 奥氮平联合氟西汀SMD为0·41(95%CI 0·19-0·64),拉莫三嗪SMD为0·16(95%CI 0·03-0·29)。
- 证据置信度采用CINeMA评估,上述药物对比安慰剂为中等置信度。
临床怎么用
- 奥氮平联合氟西汀、喹硫平、奥氮平、鲁拉西酮、鲁美哌隆、卡利拉嗪和拉莫三嗪可作为成人急性双相抑郁的循证选择。
- 处方抗抑郁药时需权衡疗效与躁狂转换风险,抗精神病药躁狂转换风险较低。
- 选择药物时应考虑各药物不同的副作用谱。
局限性
- ethnicity数据不可用。
- 部分药物证据置信度极低至低。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Bipolar depression constitutes a major public health problem due to its substantial burden of disease. Although pharmacological interventions are available, guidelines required updated evidence synthesis to improve their current recommendations. In order to inform evidence-based prescribing, we investigated the comparative efficacy and tolerability of pharmacological interventions for acute bipolar depression. METHODS: We conducted a systematic review and network meta-analysis. We searched for randomised controlled trials comparing pharmacological interventions with each other or placebo in adults with acute bipolar depression (type I, type II, or not otherwise specified), excluding those with substance misuse, unipolar depression, or schizophrenia, in MEDLINE, Embase, PsycINFO, Google Scholar, Cochrane Library, Web of Knowledge, CINAHL, and LILACS from database inception up to April 13, 2023. Criteria for eligibility were a duration of 2-16 weeks with masked outcome assessments, and we included combination, add-on design, and monotherapy studies. The co-primary outcomes were depressive symptoms, examined with standardised mean differences (SMDs), and manic switch, examined with odds ratios (ORs). We also investigated dropouts due to any reason, inefficacy, adverse events, and important side-effects as secondary outcomes. The confidence in the evidence was evaluated using Confidence-In-Network-Meta-Analysis (CINeMA). The study was registered with PROSPERO, CRD42020171726. RESULTS: We analysed data from 101 randomised controlled trials covering 20 081 participants, 8063 men (41·7%) and 11 263 women (58·3%; sex not available in four studies), mean age 41·0 years (range of means 28·7-53·6 years), and 68 medications and placebo. Ethnicity data were not available. With moderate confidence in the evidence, olanzapine plus fluoxetine, quetiapine, olanzapine, lurasidone, lumateperone, cariprazine, and lamotrigine were more efficacious than placebo in reducing depressive symptoms, with SMDs ranging from 0·41 (95% CI 0·19-0·64) for olanzapine plus fluoxetine to 0·16 (0·03-0·29) for lamotrigine. Several other drugs might also be efficacious, but the confidence in the evidence was very low to low. Antidepressants as a class seem to be efficacious, but had a higher risk for manic switch compared to antipsychotics. Medications differed in their side-effect profiles. INTERPRETATION: This is, to our knowledge, the largest network meta-analysis of pharmacotherapy for bipolar depression to date. Olanzapine plus fluoxetine, quetiapine, olanzapine, lurasidone, lumateperone, cariprazine, and lamotrigine were found to be more efficacious than placebo in adults with acute bipolar depression, with good confidence in the evidence, and to differ in their side-effect profiles. These findings can inform evidence-based care and the development of treatment guidelines internationally. FUNDING: None.
引用
- Yildiz A, Siafis S, Mavridis D, et al. Comparative efficacy and tolerability of pharmacological interventions for acute bipolar depression in adults: a systematic review and network meta-analysis. Lancet Psychiatry. 2023. PMID: 37595997. doi:10.1016/S2215-0366(23)00199-2
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。